Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients’ prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. H...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/2/181 |
| _version_ | 1827757934608646144 |
|---|---|
| author | Marco Russano Giulia La Cava Alessio Cortellini Fabrizio Citarella Alessandro Galletti Giuseppina Rita Di Fazio Valentina Santo Leonardo Brunetti Alessia Vendittelli Iacopo Fioroni Francesco Pantano Giuseppe Tonini Bruno Vincenzi |
| author_facet | Marco Russano Giulia La Cava Alessio Cortellini Fabrizio Citarella Alessandro Galletti Giuseppina Rita Di Fazio Valentina Santo Leonardo Brunetti Alessia Vendittelli Iacopo Fioroni Francesco Pantano Giuseppe Tonini Bruno Vincenzi |
| author_sort | Marco Russano |
| collection | DOAJ |
| description | Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients’ prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers. |
| first_indexed | 2024-03-11T08:58:28Z |
| format | Article |
| id | doaj.art-f55a553b360a4539a45b390175c8372f |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T08:58:28Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-f55a553b360a4539a45b390175c8372f2023-11-16T19:58:29ZengMDPI AGCurrent Oncology1198-00521718-77292023-02-013022366238710.3390/curroncol30020181Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and BiomarkersMarco Russano0Giulia La Cava1Alessio Cortellini2Fabrizio Citarella3Alessandro Galletti4Giuseppina Rita Di Fazio5Valentina Santo6Leonardo Brunetti7Alessia Vendittelli8Iacopo Fioroni9Francesco Pantano10Giuseppe Tonini11Bruno Vincenzi12Department of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDivision of Medical Oncology, San Camillo Forlanini Hospital, 00152 Roma, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Via Álvaro del Portillo, 21, 00128 Rome, ItalyImmunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients’ prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.https://www.mdpi.com/1718-7729/30/2/181immunotherapynon-small cell lung cancerimmune checkpoint inhibitorsPD-1/PD-L1 antibodiescombination strategiesbiomarkers |
| spellingShingle | Marco Russano Giulia La Cava Alessio Cortellini Fabrizio Citarella Alessandro Galletti Giuseppina Rita Di Fazio Valentina Santo Leonardo Brunetti Alessia Vendittelli Iacopo Fioroni Francesco Pantano Giuseppe Tonini Bruno Vincenzi Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers Current Oncology immunotherapy non-small cell lung cancer immune checkpoint inhibitors PD-1/PD-L1 antibodies combination strategies biomarkers |
| title | Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers |
| title_full | Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers |
| title_fullStr | Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers |
| title_full_unstemmed | Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers |
| title_short | Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers |
| title_sort | immunotherapy for metastatic non small cell lung cancer therapeutic advances and biomarkers |
| topic | immunotherapy non-small cell lung cancer immune checkpoint inhibitors PD-1/PD-L1 antibodies combination strategies biomarkers |
| url | https://www.mdpi.com/1718-7729/30/2/181 |
| work_keys_str_mv | AT marcorussano immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT giulialacava immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT alessiocortellini immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT fabriziocitarella immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT alessandrogalletti immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT giuseppinaritadifazio immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT valentinasanto immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT leonardobrunetti immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT alessiavendittelli immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT iacopofioroni immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT francescopantano immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT giuseppetonini immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers AT brunovincenzi immunotherapyformetastaticnonsmallcelllungcancertherapeuticadvancesandbiomarkers |